HOME >> BIOLOGY >> NEWS
Biomedicines presents promising results from phase II trials of omega interferon for the treatment of hepatitis C

tectable in blood despite treatment with alpha interferon. Within 48 hours of the initiation of treatment with omega interferon, HCV RNA fell sharply in all patients, and in some to undetectable levels.

Chief Executive Officer Dr. Mark Moran said, "We are pleased with these results. We believe they also support our new drug delivery efforts with this drug. In collaboration with ALZA, we are also putting omega interferon into the implantable DUROS delivery system. With DUROS, we hope to be able to deliver omega interferon for months with a single administration.

Hepatitis C infection can lead to severe impairment of liver function, liver fibrosis, and liver cancer. According to the U.S. Center for Disease Control, HCV infects nearly 3 million people in the United States, and the World Health Organization estimates 170 million people are infected worldwide. Many infected persons are unaware of the infection. The spread of HCV infection has reached epidemic proportions, as some experts believe that without substantial improvements in treatment, the death toll from HCV infection will surpass that from HIV.


'"/>

Contact: Emily Katz
e.katz@noonanrusso.com
415-677-4455
Noonan/Russo Communications
12-Nov-2001


Page: 1 2

Related biology news :

1. DFG presents the 2004 MAK and BAT value lists
2. VIB presents its annual results at BIO2004 in San Francisco
3. Steroid-coated DNA represents new approach to gene delivery
4. ASH presents advocacy awards to Sen. Dianne Feinstein and Claude Lenfant, M.D.
5. DFG presents the new MAK and BAT Value List 2003
6. Center for Health Law and Policy presents program on bioterrorism measures and civil liberties
7. Agriculture presents common ground for rural, urban people
8. UPCI presents study on estrogenic activity of medicinal botanicals
9. UPCI presents study on dendritic cells in prostate cancer
10. UPCI presents study on discovery of protein that suppresses dendritic cells
11. USF presents new research on hyperlipidemic children

Post Your Comments:
(Date:5/7/2015)... Sweden , May 7, 2015 ... touch fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest ... and FPC1035 are mainly considered for integration on ... size gives smartphone OEMs increased possibilities to integrate ... The decreased size also improves possibilities for module ...
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... -- The announcement comes as demand for ... (GRM), Ireland,s foremost records management company, ... up an impressive track record of clients within the first ... records management sector in Dubai . As ... and employ a further eight staff members at its Irish ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
(Date:5/21/2015)... PLAINSBORO, N.J. (PRWEB) May 21, 2015 ... initial circulation audit and been admitted to BPA ... result, BPA Worldwide will track audience data for ... geographic coverage. , “By becoming a member ... steadfast dedication to providing our clients with the ...
(Date:5/21/2015)... YORK , May 21, 2015  Prima Biomed ... company that is striving to become a leader in ... cancer, recently announced that the final CVac data from ... shown a clear trend for a clinically meaningful improvement ... in second remission patients. In the group ...
(Date:5/21/2015)... Calif. , May 21, 2015  The ... Orrin Hatch (R-UT) and Amy Klobuchar ... Extensions Now Accelerating Cures & Treatments, or OPEN ... rare disease patient advocacy organizations, this bipartisan legislation ... and affordable medicines to rare disease patients by ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2
Cached News: